Actinium Pharmaceuticals submits NYSE compliance plan

Actinium Pharmaceuticals, Inc. has submitted a compliance plan to NYSE American after being notified it is not meeting certain continued listing standards.

Rhea-AI Filing Summary

Actinium Pharmaceuticals, Inc. has submitted a compliance plan to NYSE American after being notified it is not meeting certain continued listing standards. The exchange requires stockholders’ equity of at least $4.0 million when a company has recorded losses in three of its four most recent fiscal years.

The plan outlines actions management intends to take to restore compliance and maintain the company’s NYSE American listing status. The filing does not detail the specific steps but confirms the plan was delivered on June 18, 2026, in response to the prior deficiency notice.

Negative

• NYSE American listing deficiency: Actinium Pharmaceuticals is not in compliance with a continued listing standard that requires stockholders’ equity of $4.0 million or more when losses have occurred in three of four recent fiscal years, creating a potential delisting risk if compliance is not restored.

Insights

Equity analyst

Actinium faces NYSE listing deficiency but has submitted a remediation plan.

Actinium Pharmaceuticals confirms it is below NYSE American’s continued listing standard tied to stockholders’ equity of $4.0 million when a company has losses in three of four recent fiscal years. This raises the risk that its shares could eventually be delisted if compliance is not restored.

The company has sent NYSE American a compliance plan describing planned actions by management to regain compliance. Actual impact will depend on whether the exchange accepts this plan and on Actinium’s ability to execute it. Future company disclosures may clarify the exchange’s response and any deadlines imposed.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Equity requirement threshold: $4.0 million stockholders’ equity Compliance plan submission date: June 18, 2026 Deficiency notice reference date: May 27, 2026

3 metrics

Equity requirement threshold $4.0 million stockholders’ equity Required under NYSE American Section 1003(a)(ii) for companies with losses

Compliance plan submission date June 18, 2026 Date Actinium submitted its NYSE American compliance plan

Deficiency notice reference date May 27, 2026 Previously reported date NYSE American notice was received

Key Terms

NYSE American, stockholders’ equity, continued listing standards, Section 1003(a)(ii), +1 more

5 terms

NYSE American financial

"In accordance with the NYSE American LLC (“NYSE American”) requirements, on June 18, 2026..."

NYSE American is a stock exchange where companies can list their shares to be bought and sold by investors. It functions like a marketplace, helping businesses raise money and providing investors with opportunities to buy ownership in these companies. Its role is important because it facilitates the trading of smaller or emerging companies, offering investors access to a broader range of investment options.

stockholders’ equity financial

"requires a listed company to maintain stockholders’ equity of $4.0 million or more..."

Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.

continued listing standards financial

"the Company was not in compliance with the continued listing standards set forth in Section 1003(a)(ii)..."

Ongoing rules a stock exchange requires a listed company to meet to keep its shares trading publicly, such as minimum share price, market value, timely financial reports, and governance practices. Think of it as a membership checklist for a club: falling short can lead to warnings or removal from the exchange, which can sharply reduce liquidity, investor confidence, and a stock’s value. Investors watch these standards to gauge regulatory risk and the stability of their holdings.

Section 1003(a)(ii) regulatory

"standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide..."

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Actinium Pharmaceuticals (ATNM) announce regarding NYSE American on June 18, 2026?

Actinium Pharmaceuticals reported that it submitted a compliance plan to NYSE American on June 18, 2026. The plan outlines management’s intended actions to restore compliance with the exchange’s continued listing standards following a prior notice of deficiency.

Why is Actinium Pharmaceuticals currently out of compliance with NYSE American standards?

NYSE American notified Actinium that it is not complying with Section 1003(a)(ii) of the NYSE American Company Guide. That standard requires stockholders’ equity of at least $4.0 million when a company has reported losses in three of its four most recent fiscal years.

What is the $4.0 million stockholders’ equity requirement mentioned for Actinium Pharmaceuticals?

The $4.0 million figure is NYSE American’s minimum stockholders’ equity requirement under Section 1003(a)(ii) when a company has losses in three of its last four fiscal years. Falling below this threshold triggered the exchange’s notice to Actinium Pharmaceuticals.

How is Actinium Pharmaceuticals responding to the NYSE American deficiency notice?

Actinium has submitted a formal compliance plan to NYSE American, describing actions management intends to take to regain compliance. The filing confirms the plan’s submission but does not provide detailed steps or timelines for how compliance will be restored.

Does the NYSE American deficiency notice mean Actinium Pharmaceuticals will be delisted?

The notice alone does not mean immediate delisting. It indicates Actinium is currently below a continued listing standard and must work with NYSE American on its submitted compliance plan. Future exchange decisions will determine whether the listing can be maintained.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 05:00 PM Learn about SEC filing dates

false 0001388320 0001388320 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2026

ACTINIUM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36374		74-2659386
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

100 Park Ave., 23rd Floor,

New York, New York 10017

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (646) 677-3870

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ATNM		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

In accordance with the NYSE American LLC (“NYSE American”) requirements, on June 18, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) submitted its compliance plan to NYSE American, outlining certain actions management intends to take in effort to restore compliance with applicable listing standards. As previously reported on May 27, 2026, the Company received a notice from NYSE American indicating that the Company was not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide, which requires a listed company to maintain stockholders’ equity of $4.0 million or more if it reported losses from continuing operations and/or net losses in three of its four most recent fiscal years.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACTINIUM PHARMACEUTICALS, INC.

Date: June 18, 2026

By:	/s/ Sandesh Seth
	Name:	Sandesh Seth
	Title:	Chairman and Chief Executive Officer

2

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB